Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
'TCELLS GONE WILD'I had never thought of this scenario.
Keeping a leash on cancer-killing cells
Redirecting the immune system to attack tumor cells is proving to be an effective therapy against cancer. However, when patients are exposed to T cells engineered to recognize and attack cancer cells, there is a risk of runaway or excessive activity or of off-target effects, both of which can themselves be deadly. Wu et al. designed T cells expressing chimeric antigen receptors that recognize and attack cancer cells with an additional control system. This mechanism would allow a doctor administering the therapy to turn the engineered T cell “on” or “off” by administering a small molecule that is required along with cancer cell antigen to stimulate the T cells and activate their tumor cell–killing properties.
Science, this issue p. 10.1126/science.aab4077
Questions:
So, what part does the $24 Million play?
So, does this deal clear up your there will never be a deal statement?
End of the week is here. What news did we have other than the gut microbiota PR? Thanks.
georgejjl Sunday, 07/14/19 01:23:19 PM
Re: None 0
Post #
201095
of 202448
This week!!!
A trifecta of GREAT NEWS regarding Anavex!!!
********************************************************************
Expect full recruitment for the PDD trial to be completed by or before 17 July 2019.
********************************************************************
Expect full recruitment for the Rett syndrome trial in the USA to be completed by or before 17 July 2019.
********************************************************************
The AAIC 2019 is the largest world wide meeting regarding Alzheimer's research. Why is there so little discussion and interest?
AAIC 2019
Exploring Gut Microbiota As a Source of Potential Biomarkers: Initial Results from the Anavex® 2-73 Alzheimer’s Disease Clinical Study
Concourse Hall 152
O4-02-04
8:45am - 9:00am
Wed, Jul 17
CANB products now in 380 physician offices.
Medical science is about to enter the 21st Century.
Exactly. CVM was one of the first companies to enter the immunotherapy world of medicine. That is the reason I first purchased in the late 1980's so I am almost a newbie here .
See what I said?
Yes, I agree this is a POS stock . I also agree that mothers should keep their kids OFF Of STOCK MESSAGE BOARDS.
Has anyone seen an update on this BACE1 inhibitor article?
https://www.dailymail.co.uk/health/article-5391081/Scientists-REVERSE-Alzheimers-middle-aged-mice.html?ito=email_share_article-top
I would have been very worried to find that the trial investigators (who most all of these were) were treating and operating on patients while actually being salesman who stayed in a Holiday Inn Express smile
Well personally, if I should have surgery and the doc is using/inserting a new medical device, I would hope the salesman is in the OR with my doc or close by. Anyone read "Pseudo Surgeon" where the docs didn't attend or pay attention to the training on the device and salesman had to be called in from the golf course to get the doc out of a jam as the patient was asleep on the operating table ?
Yes, I knew the 1.5B were authorized. I was just laughing about the "outstanding" comment.
I've been thinking about it. 1.5 Billion shares outstanding?WTF,lol?
Interesting predictions. Could you bring us up to date and results of your prior ones ? Thanks.
Are you predicting a $15 billion deal for this also?
Thanks for the info. Where do they purchase their shares?
New article on Glioblastoma in News-Medical.net
https://www.news-medical.net/news/20190623/Study-calls-for-more-aggressive-treatments-to-improve-5-year-survival-in-glioblastoma-patients.aspx
Thanks to all who attended and reported on the SH meeting. Question: my wife has arthritis in her hands and shoulder and I just ordered a jar of 100mg joint and muscle cream. From seeing the products at the meeting do you think I ordered the correct product? Thanks.
Talk about fast service. I ordered a jar of Canbiola Muscle and Joint Cream for my wife this afternoon and a little over an hour later I received a email telling me it had been shipped.
Doc, would you care to share your thoughts/evaluation/outlook of A2-73 vs Bryostatin-1?
I don't suppose anyone wanted to call me a scammer if I were a non-stockholder,lol.
I haven't read this but if you are interested here goes-
https://www.consumerlab.com/reviews/cbd-oil-hemp-review/cbd-oil/?j=860720&sfmc_sub=17839868&l=529_HTML&u=14218760&mid=7276525&jb=65&utm_medium=email&utm_source=exacttarget&utm_campaign=newsletter&utm_term=&utm_content=casein_prostate_member_de_send#toppicks
What perception would stockholders have of me, a non-stockholder, if I spent every day badmouthing a stock?
PXYN >>>>just hit 52 week high-rolling out of its hibernation.
Praxsyn Corporation is a holding company. The Company is a healthcare company focused on providing medical practitioners with medications and services for their patients. The Company, through its retail pharmacy facility in Irvine, California, formulates healthcare practitioner-prescribed medications to serve patients experiencing chronic pain. The Company is focused on non-narcotic and non-habit forming medications using therapeutic and preventative agents for pain management. In addition, it prepares products for erectile dysfunction and metabolic issues, and other ancillary products. Its products are either picked up directly at its pharmacy facility or shipped directly to patients. The Company serves patients covered under a range of insurance programs, including workers compensation programs (mainly California), preferred provider (PPO) contracts and other private insurance agreements.
PXYN>>>just hit it's 52 week high this morning.
Praxsyn Corporation is a holding company. The Company is a healthcare company focused on providing medical practitioners with medications and services for their patients. The Company, through its retail pharmacy facility in Irvine, California, formulates healthcare practitioner-prescribed medications to serve patients experiencing chronic pain. The Company is focused on non-narcotic and non-habit forming medications using therapeutic and preventative agents for pain management. In addition, it prepares products for erectile dysfunction and metabolic issues, and other ancillary products. Its products are either picked up directly at its pharmacy facility or shipped directly to patients. The Company serves patients covered under a range of insurance programs, including workers compensation programs (mainly California), preferred provider (PPO) contracts and other private insurance agreements.
In today's Sunday edition of our local newspaper a local pharmacy has a full page ad promoting their CBD product. They mention the two Boehnke and Reiman studies showing a 60% reduction of opioids use. Their product is from Ananda and state (pharmacy) "they are the highest quality CBD on the market today". That quote is to be expected in any ad but is there any truth to it?
Meeting at fleabag motel in depressed part of Long Island.
Nope, not in your usual type of accommodations but in one with worldwide known class-Marriott,lol.
OMG, how about doing some of the worlds best authorities on CNS diseases a favor by warning them they don't know what the hello they are doing by backing AVXL and its trials.
NNVC NEWS -- NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate
SHELTON, Conn., June 3, 2019 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a company with novel platform technology to fulfill unmet medical needs in treating difficult and life-threatening viral diseases, reports that it has received favorable comments from the US FDA on the Company's pre-IND application for its lead drug candidate.
The Company reports that the US FDA (the Agency) has generally agreed in its pre-IND response that the plan of drug development presented by the Company to the FDA is generally adequate at this time. The Company received the response on May 23rd, 2019.
In particular, the Agency has agreed that the Company's strategy for drug substance and drug product acceptance criteria is adequate. The Agency has further agreed that the IND-enabling non-clinical studies proposed by the Company are generally adequate. The US FDA also said that the proposed design of the IND-opening human clinical studies appears reasonable at this time.
The FDA has made valuable suggestions in the pre-IND response. The additional non-clinical studies recommended by the Agency are generally consistent with the Company's planned IND-enabling non-clinical studies. The Company has discussed the Agency's comments and suggestions in detail with its regulatory consultants from Biologics Consulting Group, VA.
"This is an important milestone that takes our lead drug closer to an IND filing," commented Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "We are very pleased with the FDA response."
The Company is now proceeding with completing the IND-enabling studies, and is working towards engaging appropriate clinical study sites and developing concrete clinical study plans.
The Company has chosen NV-HHV-101, a broad-spectrum drug candidate in its HerpeCide™ program, as its lead candidate. This candidate is formulated as a skin cream for the treatment of shingles rash, the Company's first target indication. Shingles is caused in adults by varicella zoster virus (VZV), the same virus that causes chickenpox in children. The chickenpox virus remains latent in the nerve ganglia, and breaks out into shingles rash generally due to immune-compromised status. NV-HHV-101 is designed to mimic the herpesvirus binding site on the herpesvirus entry mediator (HVEM), the classical receptor for HSV-1 and HSV-2. The Company found in its own work in cell culture studies that the same drug, in addition to working against HSV-1 and HSV-2, also worked against VZV, although it is not known in scientific literature whether VZV uses HVEM to infect cells. The Company intends to develop drugs for the HSV-2 ("genital ulcers") and HSV-1 ("cold sores") indications as the VZV program moves into the clinic.
The drug candidate NV-HHV-101 is a nanomedicine composed of a flexible polymeric micelle "backbone" to which a number of small chemical ligands are chemically attached. The ligands in this case are designed to mimic the binding site of the herpesviruses on HVEM, based on molecular modeling. NV-HHV-101 is expected to bind to VZV via a number of binding sites (i.e. the ligands), thereby encapsulating the virus particle and destroying its ability to infect human cells. This "Bind, Encapsulate, Destroy" nanoviricide® strategy is distinctly different from the mechanism of action of existing antiviral drugs against VZV.
There is a significant unmet medical need for the topical treatment of shingles rash. An effective therapy has been estimated to have a market size into several billions of dollars, if it reduces PHN incidence. An effective therapy against shingles rash reduction alone is estimated to have a market size of several hundred million dollars to low billion dollars. These market size estimates have taken into account the potential impact of the new Shingrix® GSK vaccine and the impact of the existing Zostavax® vaccine.
The Company currently intends to perform clinical studies for shingles rash reduction, which would enable a sub-billion dollar market opportunity. As experience with the drug is developed, it would be possible to extend the indication to cover PHN thereby expanding the market opportunity.
About NanoViricides
NanoViricides, Inc. (http://www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company's nanomedicines technologies are based on the TheraCour® polymeric-micelle based nanomedicine technologies of TheraCour Pharma, Inc., from which the Company has obtained licenses for developing drugs against a number of viruses. A license for VZV is in progress. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
FDA refers to US Food and Drug Administration. IND refers to investigational drug application. API refers to active pharmaceutical ingredient.
View original content to download multimedia: http://www.prnewswire.com/news-releases/nanoviricides-has-received-favorable-fda-comments-on-its-pre-ind-application-for-the-lead-drug-candidate-300860323.html
Right on target Ike as your post correlates with this one I posted a few days ago.
cfoofme Friday, 05/31/19 08:54:41 AM
Re: iwasadiver post# 229975 0
Post #
229986
of 230935
My thoughts exactly. I've posted on biotech stock boards before that 80% of investors shouldn't invest in this area because they look at a bio as just another "widget", plan this week, manufacture next week, and sell the next.
After college, I worked with a big pharma company for three years and then retired from an international medical device (diagnostics) company, so I am well versed in delays getting a drug/device to market and then even having it recalled by FDA. I bought my first biotech stock in 1987 and guess what? It is presently completing its P3 trials. If I described all the "hoops" it has encountered I would be here half a day.
If one does not have patience one should never invest in biotech.
My thoughts exactly. I've posted on biotech stock boards before that 80% of investors shouldn't invest in this area because they look at a bio as just another "widget", plan this week, manufacture next week, and sell the next.
After college I worked with a big pharma company for three years and then retired from a international medical device (diagnostics) company, so I am well versed in delays getting a drug/device to market and then even having it recalled by FDA. I bought my first biotech stock in 1987 and guess what? It is presently completing its P3 trials. If I described all the "hoops" it has encountered I would be here half a day.
If one does not have patience one should never invest in biotech.
No problem for stockholders. Most understand Business 101 for new startup companies.
Am I believing my memory or do I have lying eyes? I thought I saw where CVM insiders bought at $6.86 a few weeks back and this week some stockholders (non-insiders) are selling in the fours and fives.
I put in a buy order at $4.85 then changed it to $4.65 an hour later and picked up a few more.
Personally, I've been on message boards long enough to easily sift out Blatant BS and lies.
Don't worry, just another uneducated scammer publishing a uneducated hack job on Seeking Alpha. Someone who doesn't know a biotech from a banana.
Think this could be a 15 Billion dollar deal also?
"Close red"? Looks like a nice green to me and I'm partially color blind.
I went to the Canbiola website, looked under contacts, filled out the form with my name and a question, tried to send and that message popped up.